title: Meningococcal B vaccine development and evaluation of efficacy.
abstract: In this commentary we stress that serum bactericidal activity is now internationally accepted as correlate of protection for evaluating new vaccines for epidemic and endemic meningococcal B control, and that the standardization of the assay and the choice of representative strains for each of the vaccine candidates are critical.
authors.affiliation: Netherlands Vaccine Institute, Bilthoven, The Netherlands. loek.van.alphen@nvi-vaccin.nl
authors.forename: Loek
authors.initials: L
authors.lastname: van Alphen
authors.forename: Germie
authors.initials: G
authors.lastname: van den Dobbelsteen
mesh_terms: D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D000942:Antigens, Bacterial / Q000276:immunology; D001770:Blood Bactericidal Activity; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D018272:Porins / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D022401:Meningococcal Vaccines; D018272:Porins; D011994:Recombinant Proteins; C057699:porin protein, Neisseria